Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

GBT440 Gets Rare Pediatric Disease Designation for SCD

December 30, 2021

The U.S. Food and Drug Administration granted rare pediatric disease designation to GBT440, a once-daily, oral, small-molecule, "anti-sickling" hemoglobin modifier, for the treatment of children with sickle cell disease (SCD).

GBT440 is being evaluated in the phase III Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization (HOPE) trial of patients with SCD ages 12 or older, as well as the HOPE-KIDS 1 study, an open-label, single- and multiple-dose trial for patients ages six to 17.

The FDA previously granted GBT440 orphan-drug and fast-track designations. GBT440 is also designated as an orphan medicinal product by the European Commission and is included in the European Medicines Agency's Priority Medicines program.

Source: Global Blood Therapeutics press release, September 5, 2017.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals